

Joint Working Agreement - Executive Summary

1. Project Name:	Improving the care of patients with metastatic soft tissue sarcoma (STS) Development of a nurse led clinic for patients receiving Olaratumab, improving clinic flow in the general sarcoma chemotherapy clinic and aiming to improve cardiac outcomes for patients receiving chemotherapy treatment for metastatic soft tissue sarcomas.
2. Organisations involved with this Joint Working Project are:	Beatson West of Scotland Cancer Centre (BWoSCC) & Lilly UK
3. The objectives for this project are:	<p>To provide a nurse led service for patients receiving maintenance Olaratumab for the treatment of metastatic soft tissue sarcomas.</p> <p>To improve patient experience by providing care via a single specialist nurse in a new nurse led clinic rather than via various registrars and consultant oncologists in the general clinic.</p> <p>To improve both patient experience and service efficiency by reducing the patients' time in clinic.</p> <p>Develop an effective pathway for immediate referral from nurse led clinic to consultant list should patients require additional support.</p> <p>Identify and implement areas for process efficiency improvement in the general clinic to release capacity.</p> <p>Provide closer screening for the late effects of anthracyclines on the heart, with appropriate referral to cardio oncology as per normal practice to better understand, and ultimately minimise late anthracycline effects on the heart.</p>
4. Roles and Responsibilities, including any funding	<p>Lilly UK</p> <p>Project management support including joint development of project plan, communication plan and maintenance of risk register.</p> <p>Management of Lilly / ABPI Joint Working process and development of JWA documents including PID, Executive Summary and Agreement.</p> <p>Further development of draft protocol as required.</p> <p>Development of outcome metrics and measures and evaluation of the service</p> <p>Process improvement work - Process mapping and time in motion studies of current clinic using Lean Six Sigma tools and methodology to:</p> <ul style="list-style-type: none"> • Measure process efficiency and identify opportunities for improvement. • Establish baseline patient wait times within clinic to compare to new model. • Reduce non-value add time, common cause variation, defects, and waste. <p>Assessment of project and dissemination of results to other centres.</p> <p>At no time will Lilly have access to patient identifiable data.</p> <p>BWoSCC</p> <p>Development of nurse led clinic protocol</p> <p>Implementation of clinic protocol including: Staff recruitment and training</p> <ul style="list-style-type: none"> • Ensuring training and competencies are met

Joint Working Agreement - Executive Summary

	<ul style="list-style-type: none"> • Clinic logistics including administerial support and clinic documentation • Referral criteria • Development of treatment protocols and inclusion criteria • Discharge <p>General project management including joint development of the project plan with Lilly UK, development of communication plan and maintenance of risk register.</p> <p>Maintenance of an audit database.</p> <p>Cardio oncology support including regular additional Echocardiograms and EGC's.</p> <p>Assessment and evaluation of service. Dissemination of results to other similar centres, write up and publication in relevant clinical press.</p> <p>Funding: Total estimated project costs <u>£72,753</u> Lilly contribution total worth £35,000 BWoSCC contribution total worth estimated £37,753</p>
5. The expected benefits for patients on delivery of this project are:	<p>Single point of contact within a nurse led clinic.</p> <p>Dedicated specialist nurse care.</p> <p>Reduced time in clinic.</p> <p>Efficient prescribing and administration of Olaratumab.</p> <p>Resilience of the service will be provided by back up from Sarcoma ANP, Sprs and Consultants in the sarcoma team.</p> <p>Prospective assessment of the long term effects of cardiac function arising due to prior Doxorubicin exposure*</p> <p>*Any adverse events will be reported as per BW0SCC Trust guidelines.</p>
6. The expected benefits for the partner organisation(s) on delivery of this project are:	<p>Database of pts receiving doxorubicin plus Olaratumab, for prospective subsequent audits.</p> <p>Increase capacity in sarcoma clinic without need for additional resources.</p> <p>Increase non-medical prescribing in the sarcoma team towards WOSCAN SACT future delivery program's target of 50%.</p> <p>Training Band 6 nursing staff, who will run this clinic after the development phase.</p>
7. The expected benefits for Lilly UK on delivery of this are:	<p>Lilly is dedicated to improving the care of the patients they make medicines for. Eli Lilly manufactures Olaratumab. Addressing additional capacity demands placed on chemotherapy services since the launch of Olaratumab will minimise possible blocks to appropriate patients receiving treatment.</p>

UK / ROI Non Promotional Certificate

Piece Type	Non Promotional
Doc Number	PP-ON-GB-0072
Product	Lilly Oncology
Doc Name	Exec Summary Oncology Glasgow
Target Audience	HCP, Payer, Patient
Detailed Audience	Publically available on Lilly.co.uk

Certification:

I certify that I have examined the final form of the material and in my belief it complies with the Local Code of Practice.	
Senior Business Certification	Louisa Stevenson Business 01-Nov-2018 07:43:51 GMT+0000
Medical Practitioner Certification	Toni Roman Medical Practitioner 01-Nov-2018 09:24:27 GMT+0000